Sphera Funds Management LTD. purchased a new stake in shares of Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 163,000 shares of the company’s stock, valued at approximately $2,753,000. Sphera Funds Management LTD. owned 0.53% of Clementia Pharmaceuticals as of its most recent SEC filing.

Separately, Victory Capital Management Inc. bought a new stake in Clementia Pharmaceuticals during the third quarter valued at about $520,000. 15.02% of the stock is owned by hedge funds and other institutional investors.

CMTA has been the topic of a number of recent analyst reports. Morgan Stanley initiated coverage on Clementia Pharmaceuticals in a report on Monday, August 28th. They set an “overweight” rating and a $27.00 price target on the stock. Wedbush started coverage on Clementia Pharmaceuticals in a report on Monday, August 28th. They set an “outperform” rating and a $26.00 price target on the stock. Leerink Swann started coverage on Clementia Pharmaceuticals in a report on Monday, August 28th. They issued an “outperform” rating and a $23.00 target price on the stock. Finally, BTIG Research started coverage on Clementia Pharmaceuticals in a report on Thursday, August 31st. They issued a “buy” rating and a $32.00 target price on the stock.

Shares of Clementia Pharmaceuticals Inc. (CMTA) opened at $16.43 on Friday. Clementia Pharmaceuticals Inc. has a twelve month low of $15.05 and a twelve month high of $18.95.

ILLEGAL ACTIVITY WARNING: “Sphera Funds Management LTD. Invests $2.75 Million in Clementia Pharmaceuticals Inc. (CMTA) Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/sphera-funds-management-ltd-invests-2-75-million-in-clementia-pharmaceuticals-inc-cmta-stock/1723012.html.

Clementia Pharmaceuticals Profile

Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.

Want to see what other hedge funds are holding CMTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clementia Pharmaceuticals Inc. (NASDAQ:CMTA).

Institutional Ownership by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Receive News & Ratings for Clementia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.